
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that the findings from its pivotal Phase 3 Launch-HTN trial on lorundrostat, a novel medication targeting uncontrolled hypertension (uHTN) and …
Mineralys Therapeutics to Present Phase 3 Data on Lorundrostat at European Hypertension Meeting Read More